Back to top
more

Hologic (HOLX)

(Real Time Quote from BATS)

$81.58 USD

81.58
587,223

-0.42 (-0.51%)

Updated Sep 18, 2024 03:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Moumi Mondal headshot

With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?

Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment perspective.

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Hologic (HOLX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Hologic (HOLX) Down 3.4% Since Last Earnings Report?

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?

Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI

Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moumi Mondal headshot

Hologic (HOLX) Q3 Results Review: How to Play the Stock Now?

Hologic's (HOLX) performance in the third quarter of fiscal 2024 marks a return to growth, along with revenues and earnings beating estimates. Read on to find out what else the stock holds.

PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y

PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.

Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y

Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.

Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised

Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.

Hologic (HOLX) International Revenue in Focus: Trends and Expectations

Examine the evolution of Hologic's (HOLX) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up

Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.